SCHEMBL50447

SCHEMBL50447

COC(=O)C(C)CC=O

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4867613 1.00
SCHEMBL30415488 1.00 SMN1; SMN2 (0.39)
SCHEMBL7668341 0.81
SCHEMBL4188929 0.79
SCHEMBL661763 0.79 SMN1; SMN2 (0.43)
SCHEMBL4382224 0.79 ALDH1A1 (0.40)
SCHEMBL12890924 0.79
SCHEMBL11259359 0.79 TSHR (0.39)
SCHEMBL27757806 0.79
SCHEMBL27528410 0.79

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Appears in 2076 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118175990-A Osmotic formulation composition comprising an acid sensitive ingredient 奥德森生物有限公司 2024-06-11 CN claimed
US-8980319-B2 Methods of producing stabilized solid dosage pharmaceutical compositions containing morphinans MALLINCKRODT LLC (US) 2015-03-17 US claimed
US-20140086987-A1 Methods of Producing Stabilized Solid Dosage Pharmaceutical Compositions Containing Morphinans MALLINCKRODT LLC (US) 2014-03-27 US claimed
US-8597681-B2 Methods of producing stabilized solid dosage pharmaceutical compositions containing morphinans MALLINCKRODT LLC (US) 2013-12-03 US claimed
US-8529955-B2 Methods of treatment using a gastric retained gabapentin dosage DEPOMED, INC. (US) 2013-09-10 US claimed
US-8440232-B2 Methods of treatment using a gastric retained gabapentin dosage DEPOMED, INC. (US) 2013-05-14 US claimed
CN-102697704-A Controlled release formulations of opioid and nonopioid analgesics ALZA CORP 2012-10-03 CN claimed
US-20120064168-A1 METHODS OF TREATMENT USING A GASTRIC RETAINED GABEPENTIN DOSAGE DEPOMED, INC. (US) 2012-03-15 US claimed
US-8119166-B2 Methods of treatment using a gastric retained gabapentin dosage DEPOMED, INC. (US) 2012-02-21 US claimed
US-20120027823-A1 METHODS OF TREATMENT USING A GASTRIC RETAINED GABAPENTIN DOSAGE DEPOMED, INC. (US) 2012-02-02 US claimed
US-5990324-A Process for producing 3-methyltetrahydrofuran MITSUBISHI GAS CHEMICAL COMPANY, INC. (JP) 1999-11-23 US claimed
EP-0869125-A1 Process for producing 3-methyltetrahydrofuran MITSUBISHI GAS CHEMICAL COMPANY, INC. (JP) 1998-10-07 EP claimed
EP-0589314-B1 Process for the preparation of 2-methyl-1,4-butanediol and 3-methyltetrahydrofuran BASF AG (DE) 1997-01-22 EP claimed
US-5536854-A Preparation of 2-methyl-1,4-butanediol and 3-methyltetrahydrofuran BASF AKTIENGESELLSCHAFT (DE) 1996-07-16 US claimed
US-5458887-A OF AN OSMOTIC CORE CONTAINING A DRUG AND A WATER SWELLABLE COMPONENT AND A WATER RESISTANT POLYMER COATING CONTAINING A COMPOUND WHICH DISSOLVES IN GASTROINTESTINAL FLUID ANDRX PHARMACEUTICALS, INC. (US) 1995-10-17 US claimed
EP-0359042-B1 Process for the isolation of 2-keto-polyhydroxy-C6-carboxylic acids, especially 2-keto-L-gulonic acid, from aqueous fermentation media BASF AG (DE) 1995-02-01 EP claimed
EP-0589314-A1 Process for the preparation of 2-methyl-1,4-butanediol and 3-methyltetrahydrofuran BASF Aktiengesellschaft (DE) 1994-03-30 EP claimed
EP-0403993-B1 PROCESS FOR THE PREPARATION OF SODIUM OR POTASSIUM L-ASCORBATE ENCO ENG AG (CH) 1992-09-23 EP claimed
EP-0326727-A1 Sustained release implant and method for preparing same INTERNATIONAL MINERALS AND CHEMICAL CORPORATION (US) 1989-08-09 EP claimed
US-4761289-A Sustained release implant and method for preparing same INTERNATIONAL MINERALS & CHEMICAL CORP. (US) 1988-08-02 US claimed